<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087386</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01453</org_study_id>
    <secondary_id>04-056</secondary_id>
    <secondary_id>NCI-6480</secondary_id>
    <secondary_id>CDR0000374980</secondary_id>
    <secondary_id>MSKCC-04056</secondary_id>
    <secondary_id>N01CM62206</secondary_id>
    <nct_id>NCT00087386</nct_id>
  </id_info>
  <brief_title>Tanespimycin in Treating Patients With Stage III-IV Melanoma</brief_title>
  <official_title>Phase II Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted in EPL Diluent (NSC #704057) in Metastatic Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well tanespimycin works in treating patients with stage&#xD;
      III or stage IV melanoma. Antitumor antibiotics such as tanespimycin may stop the growth of&#xD;
      melanoma by stopping blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine if treatment with 17-AAG results in measurable anti-tumor effects and calculate&#xD;
      the proportion of clinical responses.&#xD;
&#xD;
      II. Test the hypothesis that treatment with 17-AAG can disrupt the MAPK pathway by depleting&#xD;
      intra-tumor stores of RAF kinases and/or downstream proteins such as phospho-ERK, CDK4 and&#xD;
      cyclin D1.&#xD;
&#xD;
      III. Determine if either of these effects correlates with the presence of mutated BRAF within&#xD;
      the melanoma tumor.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to presence of BRAF&#xD;
      mutation in tumor (yes vs no).&#xD;
&#xD;
      Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every&#xD;
      56 days in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete and partial response)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with stable disease</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicities</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage III Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment (tanespimycin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tanespimycin)</arm_group_label>
    <other_name>17-AAG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tanespimycin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed melanoma&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
          -  No primary melanoma of the choroid or mucosa&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion &gt;= 20 mm by conventional techniques&#xD;
                  OR &gt;= 10 mm by spiral CT scan&#xD;
&#xD;
          -  Tumor amenable to biopsy (for the first 10 patients in each stratum only)&#xD;
&#xD;
               -  Patients must have measurable disease in addition to the tumor(s) to be biopsied&#xD;
&#xD;
          -  No brain or epidural metastases&#xD;
&#xD;
               -  Completely resected solitary brain metastases allowed provided patient has been&#xD;
                  free of CNS metastases for &gt;= 6 months&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  WBC &gt;= 3,000/mm^3&#xD;
&#xD;
          -  AST and ALT =&lt; 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No history of myocardial infarction&#xD;
&#xD;
          -  No history of prolonged QTc interval&#xD;
&#xD;
          -  No active ischemic heart disease within the past 12 months&#xD;
&#xD;
          -  No uncontrolled dysrhythmia or dysrhythmias requiring medication&#xD;
&#xD;
          -  No congenital prolonged QT syndrome&#xD;
&#xD;
          -  No left bundle branch block&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)&#xD;
&#xD;
          -  No prior serious allergic reaction to eggs&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No active or ongoing infection requiring systemic antimicrobial treatment&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic melanoma&#xD;
&#xD;
               -  Prior vaccines, cytokines, or interferon alfa is not considered prior therapy&#xD;
                  unless administered with a chemotherapy drug&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior radiotherapy dose =&lt; 3,000 cGy to fields including substantial marrow&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy field that included the heart (e.g., mantle)&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent medications that may prolong the QTc interval&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent treatment with any of the following medications or herbal remedies:&#xD;
&#xD;
               -  Inhibitors of CYP3A4:&#xD;
&#xD;
                    -  Fluconazole&#xD;
&#xD;
                    -  Itraconazole&#xD;
&#xD;
                    -  Ketoconazole&#xD;
&#xD;
                    -  Macrolide antibiotics (azithromycin, clarithromycin, erythromycin, or&#xD;
                       troleandomycin)&#xD;
&#xD;
                    -  Midazolam&#xD;
&#xD;
                    -  Nifedipine&#xD;
&#xD;
                    -  Verapamil&#xD;
&#xD;
                    -  Diltiazem&#xD;
&#xD;
                    -  Terfenadine&#xD;
&#xD;
                    -  Cyclosporine&#xD;
&#xD;
                    -  Cisapride&#xD;
&#xD;
               -  Inducers of CYP3A4:&#xD;
&#xD;
                    -  Carbamazepine&#xD;
&#xD;
                    -  Phenobarbital&#xD;
&#xD;
                    -  Phenytoin&#xD;
&#xD;
                    -  Rifampin&#xD;
&#xD;
               -  Herbal extracts and tinctures with CYP3A4 inhibitory activity:&#xD;
&#xD;
                    -  Hydrastis canadensis (goldenseal)&#xD;
&#xD;
                    -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
                    -  Uncaria tomentosa (cat's claw)&#xD;
&#xD;
                    -  Echinacea angustifolia roots&#xD;
&#xD;
                    -  Trifolium pratense (wild cherry)&#xD;
&#xD;
                    -  Matricaria chamomilla (chamomile)&#xD;
&#xD;
                    -  Glycyrrhiza glabra (licorice)&#xD;
&#xD;
                    -  Dillapiol&#xD;
&#xD;
                    -  Hypericin&#xD;
&#xD;
                    -  Naringin&#xD;
&#xD;
          -  No other concurrent herbal extracts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Chapman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

